Lancet oncol:3期试验:FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗

2020-03-17 MedSci原创 MedSci原创

开放性的随机化3期试验,共679位18-75岁的不能切除的、既往未治疗过的转移性结直肠癌患者。

研究显示,与FOLFIRI(氟尿嘧啶、甲酰四氢叶酸和伊立替康)疗法相比,FOLFOXIRI (氟尿嘧啶、甲酰四氢叶酸、奥沙利铂和伊立替康)联合贝伐单抗可改善转移性结直肠癌患者预后。但与预先计划的双重序贯策略相比,预先暴露于这三种细胞毒性药物的实际益处尚不清楚,该方案在疾病进展后的可行性或有效性也不清楚。

研究人员开展一开放性的随机化3期试验,招募18-75岁的不能切除的、既往未治疗过的转移性结直肠癌患者,将患者1:1分至两组,对比先予以FOLFOXIRI治疗,然后在疾病进展后再采用相同的治疗方案,与mFOLFOX6(氟尿嘧啶、甲酰四氢叶酸和奥沙利铂)和FOLFIRI双链联合贝伐珠单抗序贯治疗的效果。

2015年2月26日-2017年5月15日,共招募了679位患者接受治疗(对照组 340人,实验组 339人)。截止2019年7月30日,中位随访了35.9个月(IQR 30.1-41.4)。实验组和对照组的中位无进展存活期分别是19.2个月(95% CI 17.3-21.4)和16.4个月(15.1-17.5;HR 0.74,95% CI 0.63-0.88;p=0.0005)。在一线化疗过程中,最常见的全因3-4级事件有腹泻(实验组 vs 对照组:57例[17%] vs 18例[5%])、中性粒细胞减少(168[50%] vs 71[21%])和房颤(25[7%] vs 35[10%])。实验组和对照组分别发生84例(25%)和56例(17%)重度不良反应事件,另外分别有8例和4例治疗相关死亡。首次病程进展后,除了神经毒性(仅实验组发生了6例)外,两组间的3-4级不良反应事件发生率无明显差异。首次病程进展后,实验组和对照组分别发生了20例(15%)和25例(12%)重度不良反应事件,3例和4例治疗相关死亡。

对于本研究纳入的转移性结直肠癌患者,预先予以FOLFOXIRI联合贝伐珠单抗,然后在疾病进展后再次予以相同的治疗方案似乎是比双药联合贝伐珠单抗序贯化疗的疗效更好。

原始出处:
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-11-02 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-05-26 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-19 linlin2314
  7. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1865805, encodeId=ba991865805ea, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Nov 02 04:09:43 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 13 02:09:43 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830527, encodeId=fb2a183052e81, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 26 23:09:43 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386601, encodeId=1e61138660120, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453359, encodeId=248c145335948, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477049, encodeId=992414e704995, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7568, encryptionId=0529e56859, topicName=FOLFIRI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564180, encodeId=9b44156418090, content=<a href='/topic/show?id=c80d30641d1' target=_blank style='color:#2F92EE;'>#再治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30641, encryptionId=c80d30641d1, topicName=再治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4415287515, createdName=whmdzju, createdTime=Thu Mar 19 11:09:43 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-19 whmdzju

相关资讯

NEJM:术后胰腺癌大突破,总生存延长近20个月!

研究认为,氟尿嘧啶、亮氨酸、伊立替康和奥沙利铂联合治疗方案,较吉西他滨可显著延长胰腺癌术后患者的生存期